Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Emerging technologies new antibody based technologies

555 views

Published on

The therapeutic monoclonal antibody market, the industry's fastest growing molecule type sector, is expected to maintain its impressive growth out to 2016. Within this market an emerging class of therapies will increase in importance over the coming six years, which will be introduced in this report. Additionally, the key companies and pipeline candidates for each technology will be profiled.

  • Be the first to comment

  • Be the first to like this

Emerging technologies new antibody based technologies

  1. 1. Emerging Technologies: New Antibody-Based TechnologiesPublished:September 2011No.Of Pages:62Price:US $ 5700IntroductionThe therapeutic monoclonal antibody market, the industrys fastest growing molecule typesector, is expected to maintain its impressive growth out to 2016. Within this market anemerging class of therapies will increase in importance over the coming six years, which willbe introduced in this report. Additionally, the key companies and pipeline candidates foreach technology will be profiled.Features and benefits* Gain insight into the sectors outlook across the next 6 years* Analyze each technologys pipeline candidates and the respective key companies involvedHighlightsSix new antibody-based technologies will be introduced with the key players for each of thetechnologies profiled. A full pipeline assessment of technology (from preclinical to latestage) will be provided. Finally, the market forecast for this emerging sector will bebenchmarked with the entire prescription pharmaceutical market.Table Of ContentsABOUT THIS REPORTPharmaVitae Explorer databaseChapter structureBiologics market dynamicsThe technologies and key playersProduct profilesData sourcingAnalyst consensusEXECUTIVE SUMMARYKey findingsIntroducing the new antibody-based technologiesThe development pipeline landscape of new antibody-based technologiesThe leading companies driving new antibody-based technology developmentNew antibody-based technology commercial return over 2010–16The MAb market will continue to be the fastest-growing sector across the entirepharmaceutical industry
  2. 2. BIOLOGICS MARKET DYNAMICSKey findingsIntroduction to the PharmaVitae company universeThe prescription pharmaceutical market performance, 2010–16Prescription pharmaceutical market performance, 2010–16Biologics driven growth, 2010–16Introduction to molecule type analysisPrescription pharmaceutical market, by molecule type, 2004–16The MAb market will continue to be the fastest growing sector across the entirepharmaceutical industryNew antibody-based technologiesAntibody-drug conjugates will be the key driver in an emerging classTHE TECHNOLOGIES AND KEY PLAYERSKey findingsOverview of the emerging antibody-based technologiesAntibody-drug conjugatesMylotargs withdrawal was a blow to the ADC marketOncology is the most active area of ADC developmentADC key playersSeattle GeneticsImmunoGenBispecific and trifunctional antibodies(Untitled sub-section)Trifunctional antibodiesDomain antibodies and nanobodiesDomain antibodies: GSK – through Domantis – leads the fieldAblynx’s nanobodiesFc-engineered antibodiesPRODUCT PROFILESRemovabAdcetrisTrastuzumab emtansineInotuzumab ozogamicinGA101/RG-7159APPENDIXReferencesDatamonitor researchExchange rates
  3. 3. LIST OF TABLESTable: Number of pipeline candidates, by company, 2011Table: New antibody-based technology market launches, 2010–16Table: MAb market sales, by technology type ($m), 2010–16Table: PharmaVitae company coverage, by peer setTable: Molecule type definitionsTable: General characteristics of small molecule drugs versus biologicsTable: Prescription pharmaceutical sales, by molecule type ($m), 2010–16Table: MAb market sales, by technology type ($m), 2010–16Table: Emerging technologies overview, 2011Table: Technology count by development stage, 2011Table: Antibody drug conjugate candidatesTable: Bispecific and trifunctional antibody candidatesTable: Domain antibody and nanobody candidatesTable: Antibody-drug conjugates candidatesTable: Removab: overviewTable: Adcetris: overviewTable: trastuzumab emtansine: overviewTable: inotuzumab ozogamicin: overviewTable: GA101/RG-7159: overviewTable: Exchange rates, 2011LIST OF FIGURESFigure: The PharmaVitae ExplorerFigure: New antibody-based technologies, preclinical-approved, 2011Figure: Total sales of the MAb market ($m and %), 2004–16Figure: Proportion of sales of the MAb market from new antibody-based technologies (%),2004–16Figure: The total pharmaceutical market outlook, sales ($m) and year-on-year growth rate(%), 2004–16Figure: Total sales of the prescription pharmaceutical market ($m), 2004–16Figure: Total sales growth of the prescription pharmaceutical market, by molecule type($bn), 2004–16Figure: Total sales of the MAb market ($m and %), 2004–16Figure: MAb market sales, by technology type ($m), 2004-16Figure: Technology count by development stage, 2011About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
  4. 4. Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×